"目录号: HY-14739
Cell Cycle/DNA DamageNF-κBMetabolic Enzyme/Protease-
Choline Fenofibrate (ABT-335)是fenofibric acid的胆碱盐，可与rosuvastatin结合作用于血脂异常。
PPARCytochrome P450
相关产品
Talarozole-GW9662-Rosiglitazone-Retinoic acid-Abiraterone acetate-Troglitazone-Pioglitazone hydrochloride-Elafibranor-GW 501516-CDDO-Im-Cobicistat-Fenofibrate-FICZ-T0070907-Wy-14643-
生物活性
Description
Choline Fenofibrate (ABT-335) is the choline salt of fenofibric acid under clinical development as a combination therapy with rosuvastatin for the management of dyslipidemia. IC50 value:Target:Several clinical trials have been developed with Choline Fenofibrate on Reverse Cholesterol Transport, Macular Edema and Hypertriglyceridemia.
Clinical Trial
NCT00463606
AstraZeneca
Hypercholesterolemia-Dyslipidemia
April 2007
Phase 3
NCT00839293
Abbott
Healthy
February 2009
Phase 1
NCT00680017
AstraZeneca
Dyslipidemia-Kidney Disease
June 2008
Phase 3
NCT00585143
AstraZeneca
Dyslipidemia, Renal Insufficiency
January 2008
Phase 1
NCT00487136
AstraZeneca
Healthy
June 2007
Phase 1
NCT00616772
AbbVie (prior sponsor, Abbott)-AbbVie
Coronary Artery Disease-Coronary Heart Disease-Dyslipidemia
February 2008
Phase 3
NCT00300430
Abbott
Dyslipidemia-Coronary Heart Disease-Mixed Dyslipidemia
September 2006
Phase 3
NCT00491530
Abbott
Mixed Dyslipidemia
June 2007
Phase 3
NCT00639158
Abbott
Dyslipidemias-Coronary Heart Disease-Combined (Atherogenic) Dyslipidemia-Mixed Dyslipidemia
February 2008
Phase 3
NCT00300456
Abbott
Dyslipidemia-Coronary Heart Disease-Mixed Dyslipidemia
March 2006
Phase 3
NCT00681525
Abbott
Pharmacokinetics
April 2008
Phase 1
NCT00728780
AstraZeneca
Adverse Events-Pharmacokinetic Variables
August 2008
Phase 1
NCT00808678
AstraZeneca
Healthy
December 2008
Phase 1
NCT00826358
AstraZeneca
Healthy
November 2008
Phase 1
NCT00300469
Abbott
Mixed Dyslipidemia-Coronary Heart Disease-Dyslipidemia
March 2006
Phase 3
NCT00300482
Abbott
Dyslipidemia-Coronary Heart Disease-Mixed Dyslipidemia
March 2006
Phase 3
NCT00681395
AstraZeneca
Adverse Events-Pharmacokinetic
May 2008
Phase 1
NCT00728910
University of Pennsylvania-Abbott
Dyslipidemia
June 2008
Phase 2
NCT00673881
Radiant Research
Dyslipidemia
March 2008
Phase 1-Phase 2
NCT00683176
Abbott Products-Abbott
Diabetic Macular Edema
September 2008
Phase 2
NCT00463606
AstraZeneca
Hypercholesterolemia-Dyslipidemia
April 2007
Phase 3
NCT00839293
Abbott
Healthy
February 2009
Phase 1
NCT00680017
AstraZeneca
Dyslipidemia-Kidney Disease
June 2008
Phase 3
NCT00585143
AstraZeneca
Dyslipidemia, Renal Insufficiency
January 2008
Phase 1
NCT00487136
AstraZeneca
Healthy
June 2007
Phase 1
NCT00616772
AbbVie (prior sponsor, Abbott)-AbbVie
Coronary Artery Disease-Coronary Heart Disease-Dyslipidemia
February 2008
Phase 3
NCT00300430
Abbott
Dyslipidemia-Coronary Heart Disease-Mixed Dyslipidemia
September 2006
Phase 3
NCT00491530
Abbott
Mixed Dyslipidemia
June 2007
Phase 3
NCT00639158
Abbott
Dyslipidemias-Coronary Heart Disease-Combined (Atherogenic) Dyslipidemia-Mixed Dyslipidemia
February 2008
Phase 3
NCT00300456
Abbott
Dyslipidemia-Coronary Heart Disease-Mixed Dyslipidemia
March 2006
Phase 3
NCT00681525
Abbott
Pharmacokinetics
April 2008
Phase 1
NCT00728780
AstraZeneca
Adverse Events-Pharmacokinetic Variables
August 2008
Phase 1
NCT00808678
AstraZeneca
Healthy
December 2008
Phase 1
NCT00826358
AstraZeneca
Healthy
November 2008
Phase 1
NCT00300469
Abbott
Mixed Dyslipidemia-Coronary Heart Disease-Dyslipidemia
March 2006
Phase 3
NCT00300482
Abbott
Dyslipidemia-Coronary Heart Disease-Mixed Dyslipidemia
March 2006
Phase 3
NCT00681395
AstraZeneca
Adverse Events-Pharmacokinetic
May 2008
Phase 1
NCT00728910
University of Pennsylvania-Abbott
Dyslipidemia
June 2008
Phase 2
NCT00673881
Radiant Research
Dyslipidemia
March 2008
Phase 1-Phase 2
NCT00683176
Abbott Products-Abbott
Diabetic Macular Edema
September 2008
Phase 2
View MoreCollapse
References
[1].Jones PH, Bays HE, Davidson MH et al. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. Clin Drug Investig. 2008;28(10):625-34.
[2].Mohiuddin SM, Pepine CJ, Kelly MT et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J. 2009 Jan;157(1):195-203.
[3].Zhu T, Awni WM, Hosmane B et al. ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. J Clin Pharmacol. 2009 Jan;49(1):63-71.
[4].Goldberg AC, Bays HE, Ballantyne CM et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009 Feb 15;103(4):515-22.
[5].Campbell J, Mohiuddin SM. The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes. Drugs Today (Barc). 2010 Oct;46(10):757-64.